Dermira Inc.'s eczema drug lebrikizumab has been granted a fast-track designation from the U.S. Food and Drug Administration.
Eczema is a common chronic skin condition that makes skin thick, dry, red and itchy. Lebrikizumab treats a type of the condition called atopic dermatitis, the most common and severe form.
The FDA grants fast-track designation to therapies that treat serious conditions and fulfill an unmet medical need. Therapies that gain the designation are eligible for expedited review and other perks.
Lebrikizumab has already undergone a phase 2 clinical trial, where the therapy was found to improve patients' skin. Dermira is conducting two late-stage clinical trials called Advocate 1 and Advocate 2 to confirm the results.
Shares of Menlo Park, Calif.-based Dermira spiked 8.54% after the markets opened Dec. 10, to $9.87. The biopharmaceutical company, which focuses on chronic skin conditions, saw its shares nearly double after the successful phase 2 results were issued in March.